Results 111 to 120 of about 8,521 (239)
Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators [PDF]
, 2015 Nucleotide-based drug candidates such as antisense oligonucleotides, aptamers, immunoreceptor-activating nucleotides, or (anti)microRNAs hold great therapeutic promise for many human diseases.
Advani +44 more
core +3 more sources
JGH Open, Volume 9, Issue 8, August 2025.ABSTRACT Background Portal vein thrombosis (PVT) contributes substantially to morbidity and mortality in cirrhotic patients. A clear insight into the anticoagulation therapy benefits in these patients could improve clinical decision‐making. This meta‐analysis aimed to assess the efficacy and safety of Anticoagulants in cirrhotic patients with PVT ...
Muhammad Hassan Waseem +14 more
wiley +1 more source
Synthetic flavonoids as novel modulators of platelet function and thrombosis [PDF]
, 2019 Cardiovascular diseases represent a major cause of mortality and morbidity in the world and thrombotic conditions such as heart attacks and strokes are caused by unwarranted activation of platelets and subsequent formation of blood clots (thrombi) within
Dina A. I. Albadawi +7 more
core +1 more source
British Journal of Pharmacology, Volume 182, Issue 16, Page 3838-3851, August 2025.Abstract Background and Purpose The C‐type lectin‐like receptor‐2 (CLEC‐2) is a platelet receptor for the endogenous ligand podoplanin. This interaction contributes to several (patho)physiological processes, such as lymphangiogenesis, preservation of blood and lymphatic vessel integrity organ development, and tumour metastasis.
Marcin A. Sowa +8 more
wiley +1 more source
Redox Proteomics and Platelet Activation: Understanding the Redox Proteome to Improve Platelet Quality for Transfusion. [PDF]
, 2017 Blood banks use pathogen inactivation (PI) technologies to increase the safety of platelet concentrates (PCs). The characteristics of PI-treated PCs slightly differ from those of untreated PCs, but the underlying reasons are not well understood.
Abonnenc, M. +4 more
core +1 more source
Mechanical Biomimetic Nanocomposites for Multidimensional Treatment of Arterial Thrombosis
Advanced Science, Volume 12, Issue 25, July 3, 2025.In this study, a mechanical biomimetic nanocomposite is developed, guided by photoacoustic imaging, to achieve highly efficient and safe thrombolysis through the synergistic effects of photothermal therapy and pharmacological intervention. Most notably, the nanoparticle improves the microenvironment of arterial thrombi, marked by high shear stress and ...
Ying Li +6 more
wiley +1 more source
The effects of signal transducer and activator of transcription three mutations on human platelets
Platelets, 2018 Involvement of signal transducer and activator of transcription 3 (STAT3) in inflammation is well known. Recently, a role for STAT3 in platelet activation and platelet production has been suggested.
Floor E. Aleva +9 more
doaj +1 more source
A humanized monoclonal antibody that inhibits platelet-surface ERp72 reveals a role for ERp72 in thrombosis [PDF]
, 2017 Background: Within the endoplasmic reticulum, thiol isomerase enzymes modulate the formation and rearrangement of disulphide bonds in newly folded proteins entering the secretory pathway to ensure correct protein folding.
Bicknell, A. B. +8 more
core +1 more source
Aggregate, Volume 6, Issue 7, July 2025.Diabetic wound healing is blocked by persistent inflammation and oxidative stress. Bioactive substances like growth factors and Hsts promote repair but lack long‐term stability. Herein, a platelet membrane‐coated nanoparticle system (PNP) is proposed to achieve enhanced retention of aggregation‐induced emissive (AIE) molecular‐modified Hst1 (Hst1‐AIE ...
Xiaoxuan Lei +9 more
wiley +1 more source
Ibrutinib inhibits platelet integrin αIIbβ3 outside-in signaling and thrombus stability but not adhesion to collagen [PDF]
, 2015 OBJECTIVE: Ibrutinib is an irreversible Bruton tyrosine kinase inhibitor approved for treatment of Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, and mantle cell lymphoma that increases the risk of bleeding among patients. Platelets from
Alexander P. Bye +6 more
core +1 more source